Effective partnering and China market assessment platform – ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations.
Who should present?
Global pharma/biotech companies:
- Looking for out-licensing opportunities in China
- With clinical-stage assets
- Focusing on Oncology, CNS, Cardiovascular, Ophthalmology, Orthopedics, Pediatrics, and GI areas
- Looking for equity investment opportunities in China (Chinese companies only)
Who are the attendees?
- 40% are Chinese pharma/biotechs looking for in-licensing opportunities to enrich pipeline
- 35% are Pharma/biotechs outside China looking for in-licensing opportunities to enrich pipeline in China and other regions
- 20% are VCs and PEs looking for pharma/biotech investment opportunities in China
Why China ?
In/out-licensing is becoming the major business strategy among Chinese pharma.
China related licensing transactions greatly increased despite of COVID-19 in 2020. There were total 129 China related cross border licensing deals including 36 out-licensing deals and 93 in-licensing deals, representing an increase of 59% y/y. Most notably, out-licensing deals reached 36 in 2020, versus 6 in 2019.
Why ACCESS CHINA ?
Broad Chinese Strategic Partners Coverage
Compared to other conferences such as Bio Convention or Bio Showcase, ACCESS CHINA has the broadest coverage of Chinese strategic partners and investors who are looking for in/out licensing opportunities.
Easy China Market Assessment
We gather interests for presenting companies within two weeks after the presentations, an easy and effective way to assess the level of interest in the Chinese market.
More Exposure via Different Channels
ACCESS CHINA promotes presenting companies through various channels in deluding asset listing on platform, video roadshow on live day and on demand, asset report distribution to our members, and promoting to targeted investors through email and social media.
ACCESS CHINA Biotech Forum is a quarterly corporate access event series between China and Western biopharma. It is a leading deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market, and for Chinese companies to enter the global market.
ACCESS CHINA|Boston Forum @BIO
We cordially invite you to attend the ‘ACCESS CHINA – Boston Forum @BIO’ scheduled to be held on June 4th and June 13th-15th, 2023, in Boston and online, respectively. This event is expected to be the largest China-themed gathering during the BIO Convention 2023. The main theme of the forum is “Building Effective Partnerships in…Keep reading
ACCESS CHINA is a series of events that YAFO organizes each year, including ACCESS CHINA Biotech Forum Summer showcase, East Meets West Mixing Dinner @ JPM, ACCESS CHINA BD Forum @ BIO International Convention, CHINA BD Forum (September each year), and ACCESS CHINA Online Partnering. During 2020 we have helped 333 companies to present their products in front of global pharma and VC/PEs. 5 of them have closed deals after presenting.
Selected Partnering Opportunities for Ex-China Region
Differentiated Small Molecules for Solid Tumors and Hematopoietic Malignancies
Project introduction: Established in 2010, the target company focuses on small molecule medicines which are used for cancer and immune system disorders. It has built a rich pipeline based on…Keep reading